A pilot study of bendamustine in elderly patients with high-risk MDS and AML

References

• Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006; 91: 1513–1522
   PubMed Web of Science ®Google Scholar
• Knipp S, Hildebrandt B, Giadounidis A N, Kobbe G, Haas R, Aul C, et al. Intensive chemotherapie is not recommended for patients with AML or high-risk MDS aged over 60 years with complete karyotype anormalities. Blood 2004; 104, Abstract 72
   Web of Science ®Google Scholar
• de Witte T, Oosterveld M, Muus P. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome. Blood Rev 2007; 21: 49–55
   PubMed Web of Science ®Google Scholar
• Hallemeier C L, Girgis M D, Blum W G, Brown R A, Khoury H J, Devine S M, et al. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 2006; 12: 749–757
   PubMed Web of Science ®Google Scholar
• Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, et al. Prospective feasibility analysis of reduced intensity conditioning regimens (RIC) for hematopoetic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007; 109: 1395–1400
   PubMed Web of Science ®Google Scholar
• Elliott M A, Tefferi A, Hogan W J, Letendre L, Gastineau D A, Ansell S M, et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006; 37: 1003–1008
   PubMed Web of Science ®Google Scholar
• de Lima M, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol 2006; 43: 107–117
   PubMed Web of Science ®Google Scholar
• Herold M, Schulze A, Niederwieser D, Franke A, Fricke H J, Richter P, , for the East German Study Group Hematology and Oncology (OSHO), et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006; 132: 105–112
   PubMed Web of Science ®Google Scholar
• Weidmann E, Kim S Z, Rost A, Schuppert H, Seipelt G, Hoelzer D, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1285–1289
   PubMed Web of Science ®Google Scholar
• Ponisch W, Mitrou P S, Merkle K, Herold M, Assmann M, Wilhelm G, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone – a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132: 205–212
   PubMed Web of Science ®Google Scholar
• Balfour J A, Goa K L. Bendamustine. Drugs 2001; 61: 631–640
   PubMed Web of Science ®Google Scholar
• Mutschler E, Schäfer-Korting M. Arzneimittelwirkungen. Lehrbuch der Pharmakologie und Toxikologie7th edn. Wiss. Verl.-Ges., Stuttgart 1996
   Google Scholar
• Ozegowski W, Krebs D. IMET 3393,g-[1-methyl-5-bis-(b-chlorethyl)-amino-benzimidazolyl-(2)]-butic acid hydrochloride, a new cytostatic agent from the benzimidazole mustard series. Zbl Pharm 1971; 110/10: 1013–1019
   Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Müller-Hermelink H K, Vardiman J, et al. World Health Organisation classification of neoplastic diseases of the hematopoetic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Bennett J M. World Health Organisation classification of the acute leucemias and myelodysplastic syndrome. Int J Hematol 2000; 72: 131–133
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodystplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Arnaudov G, Peytchev D, Merkle Kh. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006; 132: 99–104
   PubMed Web of Science ®Google Scholar
• Schoffski P, Seeland G, Engel H, Grunwald V, Paul H, Merkle K, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol 2000; 11: 729–734
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl I M, et al. Treatment of anemia of myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68–75
   PubMed Web of Science ®Google Scholar
• Bowen D, Hyslop A, Keenan N, Groves M, Culligan D, Johnson P, et al. Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia. Haematologica 2006; 91: 709–710
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266–1269
   PubMed Web of Science ®Google Scholar
• Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002; 16: 1–6
   PubMed Web of Science ®Google Scholar
• Raza A, Lisak L, Billmeier J, Pervaiz H, Mumtaz M, Gohar S, et al. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. Leuk Lymphoma 2006; 47: 433–440
   PubMed Web of Science ®Google Scholar
• Denzlinger C, Bowen D, Benz D, Gelly K, Brugger W, Kanz L. Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. Br J Haematol 2000; 108: 93–95
   PubMed Web of Science ®Google Scholar
• Lübbert M, Wijermans P W. Epigenetic therapy in MDS and acute AML: focus on decitabine. Ann Hematol 2005; 84(Suppl 13)1–2
   PubMed Web of Science ®Google Scholar
• Silverman L R, McKenzie D R, Peterson B L, Holland J F, Backstrom J T, Beach C L, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895–3903
   PubMed Web of Science ®Google Scholar
• Stemmler J, Wittmann G W, Hacker U, Heinemann V. Leukapheresis in chronic myelomonocytic leukemia with leukostasis syndrome: elevated serum lactate levels as an early sign of microcirculation failure. Leuk Lymphoma 2002; 43: 1427–1430
   PubMed Web of Science ®Google Scholar
• Porcu P, Cripe L D, Ng E W, Bhatia S, Danielson C M, Orazi A, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000; 39: 1–18
   PubMed Web of Science ®Google Scholar
• Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007; 25: 25–31
   PubMed Web of Science ®Google Scholar